Re-expression of ADAM10-ACT rescued the growth disadvantage conferred by ADAM10 KO in ALL-199 PDX cells (Fig. 4G), excluding putative off-target effects and confirming that ADAM10 activity is essential for in vivo growth. This evidence concerns the gene ADAM10 and acute lymphoblastic leukemia.